Search

Author/Creator Davis, John C

1. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). Issue 1 (2nd June 2015)

Authors:
Kalunian, Kenneth C; Merrill, Joan T; Maciuca, Romeo; McBride, Jacqueline M; Townsend, Michael J; Wei, Xiaohui; Davis, John C; Kennedy, William P
Journal:
Annals of the rheumatic diseases
Issue:
Volume 75:Issue 1(2016)
Page Start:
196
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE. Issue 1 (30th March 2015)

Authors:
Kennedy, William P; Maciuca, Romeo; Wolslegel, Kristen; Tew, Wei; Abbas, Alexander R; Chaivorapol, Christina; Morimoto, Alyssa; McBride, Jacqueline M; Brunetta, Paul; Richardson, Bruce C; Davis, John C; Behrens, Timothy W; Townsend, Michael J
Journal:
Lupus science & medicine
Issue:
Volume 2:Issue 1(2015)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. GW24-e2907 Effects of RG7652, a fully human mAb against proprotein convertase subtilisin/kexin type 9, on LDL-c: a Phase I, randomised, double-blind, placebo-controlled, single- and multiple-dose study. (1st October 2013)

Authors:
Tingley, Whittemore; Luca, Diana; Leabman, Maya; Budha, Nageshwar; Kahn, Robert; Baruch, Amos; Cowan, Kyra; Davis, John C
Journal:
Heart
Issue:
Volume 99(2013)Supplement 3
Page Start:
A153
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗